Literature DB >> 17723811

Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival.

Jung-Jyh Hung1, Chien-Ying Wang, Min-Hsiung Huang, Biing-Shiung Huang, Wen-Hu Hsu, Yu-Chung Wu.   

Abstract

OBJECTIVE: Resection is the treatment of choice for patients with stage I non-small cell lung cancer. Stage I non-small cell lung cancer has been further subdivided into IA (T1N0M0, tumor size < or = 3 cm without visceral pleural invasion) and IB (T2N0M0, tumor size > 3 cm or any size with visceral pleural invasion). The aim of this study was to evaluate the prognostic factors in patients with resected stage I non-small cell lung cancer with a diameter of 3 cm or less.
METHODS: We retrospectively reviewed the clinicopathologic characteristics of 445 patients with resected stage I non-small cell lung cancer with a diameter of 3 cm or less who were treated at Taipei Veterans General Hospital between 1980 and 2000. Disease-free survival, overall survival, and their predictors were analyzed.
RESULTS: The 5- and 10-year overall survivals were 61.4% and 40.0%, respectively. The 5- and 10-year disease-free survivals were 74.5% and 73.4%, respectively. Tumor size, smoking index, and number of mediastinal lymph nodes dissected were significant predictors for both disease-free survival (P = .009, P = .002, and P = .006, respectively) and overall survival (P = .004, P < .001, and P = .001, respectively) in multivariate analyses. Visceral pleural invasion did not influence overall survival or disease-free survival.
CONCLUSIONS: Tumor size, smoking index, and number of mediastinal lymph nodes dissected were prognostic factors for both overall survival and disease-free survival in resected stage I non-small cell lung cancer with a diameter of 3 cm or less. Small tumors (<3 cm) of stage IB (T2N0M0) non-small cell lung cancer with visceral pleural invasion should be treated as T1 disease and not T2 disease.

Entities:  

Mesh:

Year:  2007        PMID: 17723811     DOI: 10.1016/j.jtcvs.2007.04.059

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  Changes in the Surgical Treatment Strategies for Nonsmall Cell Lung Cancer in the Past 20 Years: A Single-Center Experience.

Authors:  Ahmet Üçvet; Soner Gürsoy; Serkan Yazgan
Journal:  Turk Thorac J       Date:  2020-01-01

2.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

3.  A clinicopathological study of resected non-small cell lung cancers 2 cm or less in diameter: a prognostic assessment.

Authors:  Chun-Lei Shi; Xue-Yan Zhang; Bao-Hui Han; Wei-Zhong He; Jie Shen; Tian-Qing Chu
Journal:  Med Oncol       Date:  2010-07-27       Impact factor: 3.064

4.  Visceral Pleural Invasion in Pulmonary Adenocarcinoma: Differences in CT Patterns between Solid and Subsolid Cancers.

Authors:  Benedikt H Heidinger; Ursula Schwarz-Nemec; Kevin R Anderson; Constance de Margerie-Mellon; Antonio C Monteiro Filho; Yigu Chen; Marius E Mayerhoefer; Paul A VanderLaan; Alexander A Bankier
Journal:  Radiol Cardiothorac Imaging       Date:  2019-08-29

5.  Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.

Authors:  Natália R Salinas; Camila T Lopes; Patrícia V Palma; Celina T Oshima; Valquiria Bueno
Journal:  Pathol Oncol Res       Date:  2009-02-12       Impact factor: 3.201

6.  Invasion of the inner and outer layers of the visceral pleura in pT1 size lung adenocarcinoma measuring ≤ 3 cm: correlation with malignant aggressiveness and prognosis.

Authors:  Makoto Hamasaki; Fumiaki Kato; Kaori Koga; Hiroyuki Hayashi; Mikiko Aoki; Yoshihiro Miyake; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Virchows Arch       Date:  2012-09-22       Impact factor: 4.064

7.  Prognostic factors in curatively resected pathological stage I lung adenocarcinoma.

Authors:  Yikun Yang; Yousheng Mao; Lin Yang; Jie He; Shugeng Gao; Juwei Mu; Qi Xue; Dali Wang; Jun Zhao; Yushun Gao; Zhirong Zhang; Ningning Ding; Ding Yang
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

8.  Predictors of long time survival after lung cancer surgery: a retrospective cohort study.

Authors:  Kjetil Roth; Tom Ivar Lund Nilsen; Elisabeth Hatlen; Karina Søvik Sørensen; Torstein Hole; Rune Haaverstad
Journal:  BMC Pulm Med       Date:  2008-10-27       Impact factor: 3.317

9.  Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer.

Authors:  D J Pinato; R J Shiner; M J Seckl; J Stebbing; R Sharma; F A Mauri
Journal:  Br J Cancer       Date:  2014-03-25       Impact factor: 7.640

10.  Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.

Authors:  Pei Zhang; Jianchun Duan; Hua Bai; Zhijie Wang; Shugeng Gao; Fengwei Tan; Yushun Gao; Xin Wang; Rui Wan; Jiachen Xu; Xiran He; Xiaoshuang Feng; Ruofei Yu; Jing Sun; Zhe Zhao; Kailun Fei; Ni Li; Jie He; Jie Wang
Journal:  Thorac Cancer       Date:  2020-10-27       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.